This enduring activity targets healthcare gaps related to awareness of health disparities in the prevention and treatment of ocular diseases and the importance of diverse representation within clinical trials and the ophthalmology workforce, impacting outcomes through assessing for factors that can contribute to disparities in vision health and strategies to overcome them.

This online program targets critical issues in diabetic retinopathy, including the importance of screening and early detection of retinopathy, how early treatment in retinopathy can help prevent progression to vision-threatening complications, and the advantageous impact of multidisciplinary management in the care of a retinopathy patient. Learn essential elements of screening, referral, and treatment, as well as core systemic factors affecting risk for both development and worsening of diabetic eye disease, which when optimized can help preserve vision in diabetes.

This enduring program about retinopathy of prematurity (ROP) targets key concepts about pathophysiology and the role of vascular endothelial growth factor (VEGF), screening, and management for this potentially visually blinding disorder of premature infants. Learn essential elements for recognizing infants at risk, timelines to ROP development, current advances in treatment approaches and critical examination timeframes to help prevent progression as well as complications of advanced disease.

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

This enduring program targets critical issues in nonproliferative diabetic retinopathy (NPDR), including risk for retinopathy development and progression, how early treatment can help prevent progression to vision-threatening complications, and treatment strategies for NPDR. Learn essential elements of assessment and management, as well as clinical trial data on the latest approaches in care, helping to preserve vision in diabetes.

This interactive, case-based enduring meeting is designed to foster learner collaboration and decision-making for various presentations of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Learn and apply the latest updates in treatment, including novel therapeutic formulations as well as considerations on patient related factors and dosing strategies to individualize care in nAMD and DME.

RELEASED DATE: November 30, 2023
EXPIRATION DATE: November 30, 2024

This enduring activity focuses on individualizing therapy for the treatment of diabetic macular edema (DME). Providers will learn about the safety, efficacy, and durability of established and emerging DME therapies, as well as technological updates that can be used to facilitate patient screening, monitoring, and treatment interval decision-making. This activity uses a unique documentary approach to share a patient story along with commentary from a retinal disease expert.

RELEASED DATE: September 08, 2023
EXPIRATION DATE: September 08, 2024

This enduring activity focuses on individualizing therapy for the treatment of diabetic macular edema (DME) based on patient-, disease-, and treatment-related factors. Providers will learn about technological advancements that can help with timely diagnosis and/or effective interval monitoring of DME. Listen to a retina expert discuss the benefits and treatment burdens of conventional anti-vascular endothelial growth factor (VEGF) therapies and compare the safety, efficacy, and durability of established and emerging therapies for patients with DME.

RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024

This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD) based on patient-, disease-, and treatment-related factors. Listen to a retina expert talk about some of the technological advancements that can help with timely diagnosis and/or effective interval monitoring of nAMD, discuss the benefits and treatment burdens of conventional anti-vascular endothelial growth factor (VEGF) therapies, and compare the safety, efficacy, and durability of established and emerging therapies for patients with nAMD.

RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024

This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD). Providers will learn about the safety, efficacy, and durability of established and emerging nAMD therapies, as well as technological updates that can be used to facilitate patient screening, monitoring, and treatment interval decision-making. This activity uses a unique documentary approach to share a patient story, along with commentary from a retinal disease expert.

RELEASED DATE: October 31, 2023
EXPIRATION DATE: October 31, 2024